Most Clicked StoriesMore >


FDA allows Chimerix to conduct trials of experimental Ebola drug

BIO SmartBrief | Oct 17, 2014

The FDA has permitted Chimerix to conduct clinical trials to test brincidofovir, its experimental broad-spectrum antiviral drug, against Ebola. The emergency investigational new drug application submitted by the company was supported by data from in vitro assessments and ongoing animal testing. FDAnews (10/15)


AbbVie officially cancels $55B purchase of Shire

BIO SmartBrief | Oct 21, 2014

AbbVie to reconsider $54B merger with Shire

BIO SmartBrief | Oct 16, 2014

NewLink-Genentech's cancer drug collaboration could be worth over $1 billion

BIO SmartBrief | Oct 21, 2014

BIO urges FDA to revise draft biologic exclusivity guidelines

BIO SmartBrief | Oct 16, 2014

Report: Biotech, pharma and medtech see strong M&A activity

BIO SmartBrief | Oct 20, 2014

Idiopathic pulmonary fibrosis drugs from Roche, Boehringer win FDA approval

BIO SmartBrief | Oct 16, 2014

Pancreatic cancer drug developer applies for FDA orphan status

BIO SmartBrief | Oct 15, 2014

New molecule could hasten search for Ebola drugs

BIO SmartBrief | Oct 15, 2014

Nuvo Research licenses osteoarthritis pain drug to Horizon Pharma

BIO SmartBrief | Oct 20, 2014


Find BIO SmartBrief Issues by Date:



BIO News More >


Faster & better connections with quality R&D vendors

BIO SmartBrief | Oct 22, 2014

New BIO Survey Tool: FDA/Sponsor Interactions During Drug Development

BIO SmartBrief | Oct 21, 2014

Secure document sharing services optimized for life science organizations

BIO SmartBrief | Oct 20, 2014

Summer 2014 BIO Therapeutic Newsletters

BIO SmartBrief | Oct 17, 2014

Industrial biotechnology with a French twist!

BIO SmartBrief | Oct 16, 2014




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more